NHD Global
Metabolic & Weight Loss · Amylin analogue research
Scientific Product Dossier
Cagrilintide is a long-acting acylated amylin analogue in clinical development for metabolic and body-weight research. A dose-ranging Phase 2 study reported body-weight outcomes for cagrilintide monotherapy; combination-study results must be evaluated separately and are not evidence for the single component alone. Cagrilintide remains investigational.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
At 26 weeks, the trial reported mean body-weight changes from −6.0% to −10.8% across cagrilintide groups, compared with −3.0% for placebo.
Clinical monotherapy result for the studied intervention; not evidence for this catalog lot and not interchangeable with combination-trial outcomes.
Read the primary studyFDA states that cagrilintide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Investigational status must remain visible wherever trial outcomes are summarized.
Read the primary studyGastrointestinal adverse events were reported in 41–63% of cagrilintide groups versus 32% with placebo; nausea was reported in 20–47% versus 18%.
Trial-level tolerability data for the studied intervention; not a catalog-lot safety claim.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Randomized, double-blind, placebo-controlled human research evaluating multiple cagrilintide groups over 26 weeks.
View primary recordPrimary trial-registry record for the cagrilintide monotherapy study.
View primary recordThird-party publications selected for direct relevance.
Lau DCW, et al. The Lancet. 2021;398:2160–2172. PMID 34798060 · DOI 10.1016/S0140-6736(21)01751-7
ClinicalTrials.gov record NCT03856047.
U.S. Food and Drug Administration. Content current through May 31, 2026.
Concise answers for researchers comparing identity, evidence and catalog variants.
Cagrilintide is an investigational, long-acting acylated analogue of the peptide hormone amylin.
No. It remains an investigational compound in clinical development.
No. Combination trials study cagrilintide with semaglutide and cannot be attributed to cagrilintide monotherapy.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
A source-grounded guide to cagrilintide’s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.
Updated August 28, 2026
A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025–2026 phase 3 records and limits on transferring evidence.
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CGL5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
